首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1787989

強子療法市場，2032 年全球預測：按粒子類型、成分、癌症類型、最終用戶和地區分類

Hadron Therapy Market Forecasts to 2032 - Global Analysis By Type of Particle (Proton Therapy, Carbon Ion Therapy and Other Ion Therapy), Component (Equipment, Software and Services), Cancer Type, End User, and By Geography

出版日期: 2025年08月07日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，全球強子治療市場預計在 2025 年將達到 21 億美元，到 2032 年將達到 53 億美元，預測期內的複合年成長率為 13.6%。

強子療法是一種先進的放射療法，它使用帶電粒子（例如質子或碳離子）來代替傳統的X光。這些粒子能夠精準地將劑量釋放到腫瘤，同時最大限度地減少對周圍健康組織的損傷。強子療法以其精準度和有效性而聞名，尤其適用於治療深層癌症、抗放射治療的癌症以及關鍵部位的癌症。其臨床潛力已促使腫瘤學和醫療技術市場的投資不斷增加。

根據CNAO/MDPI通報，全球已有超過29萬名患者接受質子束治療，每年接受治療的患者超過3.5萬名。

全球癌症發生率上升

全球癌症發生率的持續上升極大地推動了強子治療市場的發展。這一趨勢源於越來越多的患者尋求先進精準的放射線治療，而強子治療，尤其是質子和碳離子治療方法，正成為治療複雜和局部腫瘤的高效選擇。此外，精準醫療的日益成長，加上癌症類型抗治療性，正在推動對更有針對性的治療的需求。隨著全球癌症患者的快速成長，對強子治療等創新腫瘤干預措施的需求也日益成長，從而推動了市場的成長。

全球治療中心有限

建造和運作強子治療中心所需的高額資本投入嚴重限制了其在全球的佈局。這些設施需要大量的基礎設施，包括迴旋加速器、同步加速器和強大的輻射屏蔽，同時也需要依賴訓練有素的員工團隊。複雜的法規核准流程和缺乏標準化的報銷政策也構成了額外的障礙，阻礙了市場滲透，尤其是在新興市場。因此，這種資源匱乏限制了患者的可及性，延緩了強子治療在世界各地的廣泛接受，並阻礙了市場擴張。

將人工智慧融入治療計劃和影像處理

人工智慧系統簡化了重複且耗時的流程，例如自動危及器官分割和自適應重新規劃，從而簡化了工作流程並減少了人為差異。這些進步使臨床醫生能夠快速制定針對特定患者的複雜治療計劃，從而提高治療的準確性和可靠性。隨著人工智慧技術的不斷發展並獲得監管部門的核准，它不僅有望提高業務效率，還能改善接受強子治療的患者的臨床療效。

安裝和運行成本高

由於需要專用設備和嚴格的建築要求，建立此類設施需要數千萬美元的投資。諸如專業人員薪資和先進技術維護等持續支出進一步加重了財務負擔。這些成本使得病患的治療費用高昂，也為醫療保險公司帶來了挑戰。預計這些財務障礙將繼續成為永續成長的主要威脅。

COVID-19的影響：

新冠疫情擾亂了醫療保健產業，並將資源轉移至疫情應對，導致強子治療市場暫時受挫。供應鏈中斷和旅行限制導致新中心的安裝和試運行延遲，同時常規治療也因遵守感染控制通訊協定而被推遲或延期。患者就診減少，尤其由於國際旅遊限制和重症加護資源配置不足。然而，儘管存在這些短期中斷，強子治療行業仍展現出韌性，隨著醫療保健系統的適應和患者需求的恢復，該行業正在逐步恢復正常業務。

質子治療領域預計將成為預測期內最大的市場

質子治療領域預計將在預測期內佔據最大的市場佔有率，這得益於其良好的安全性，以及能夠提供高度標靶化的劑量，同時最大限度地減少對周圍組織的損傷。越來越多的臨床證據支持其在減少副作用方面的優勢，使其特別適用於兒科患者和腫瘤位於重要器官附近的患者等弱勢群體。此外，大型醫院質子治療系統的安裝日益增多，以及政府對非侵入性癌症治療的支持力度不斷加大，預計將鞏固該領域的主導地位。

預計兒童癌症領域在預測期內的複合年成長率最高

預計兒科腫瘤領域將在預測期內達到最高成長率。這主要是因為兒童尤其容易受到傳統放射療法長期副作用的影響，因此對毒性較小、療效較好的治療方法的需求日益成長。全球兒童癌症發生率的上升，加上臨床試驗的進展和兒科治療方案的技術創新，正在加劇這一趨勢。此外，政府補貼和全球衛生計劃也進一步推動了強子療法在兒童癌症治療中的應用，創造了強勁的成長前景。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。該地區擁有先進的醫療基礎設施、強大的科學研究能力以及對癌症治療技術的大量公共和私人投資。該地區受益於創新治療方法的早期應用和成熟的臨床網路，從而擴大了患者的可及性。此外，主要設備製造商的存在以及持續擴大強子治療設施的努力（尤其是在美國），確保了北美在臨床應用方面處於領先地位。

複合年成長率最高的地區：

預計亞太地區將在預測期內實現最高的複合年成長率。醫療基礎設施投資、癌症發病率的上升以及政府和私營部門資金籌措的活性化，共同支持了這一快速成長。日本和中國憑藉著尖端研究中心和新建的強子中心取得了重大進展，而印度則憑藉著認知度的提升和官民合作關係，正成為一個充滿希望的市場。這些努力正在推動該技術的快速應用，使亞太地區成為未來成長的中心。

免費客製化服務：

此報告的訂閱者將獲得以下免費自訂選項之一：

公司簡介
- 全面分析其他市場參與者（最多 3 家公司）
- 主要企業的SWOT分析（最多3家公司）
區域細分
- 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
競爭基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲國家
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲地區

第10章：主要發展

協議、夥伴關係、合作和合資企業
收購與合併
新產品發布
業務擴展
其他關鍵策略

第11章公司簡介

Ion Beam Applications SA（IBA）
Varian Medical Systems, Inc.
Hitachi, Ltd.
Mevion Medical Systems, Inc.
Sumitomo Heavy Industries, Ltd.
Mitsubishi Electric Corporation
Koninklijke Philips NV
Advanced Oncotherapy PLC
Optivus Proton Therapy, Inc.
Elekta AB
ProTom International, Inc.
ProNova Solutions, LLC
Toshiba Energy Systems & Solutions Corporation
Provision Healthcare, LLC
Shinva Medical Instrument Co., Ltd.
Danfysik A/S
Siemens Healthineers AG

簡介目錄圖表

Product Code: SMRC30254

According to Stratistics MRC, the Global Hadron Therapy Market is accounted for $2.1 billion in 2025 and is expected to reach $5.3 billion by 2032 growing at a CAGR of 13.6% during the forecast period. Hadron therapy is an advanced form of radiation treatment that uses charged particles like protons or carbon ions instead of conventional X-rays. These particles deliver highly targeted doses to tumors while minimizing damage to surrounding healthy tissue. Known for its precision and effectiveness, hadron therapy is particularly beneficial for treating deep-seated, radiation-resistant, or critical-area cancers. Its clinical potential is driving increasing investment in oncology and medical technology markets.

According to CNAO / MDPI reporting, over 290,000 patients have been treated with protons globally, with treatments increasing by more than 35,000 patients per year.

Market Dynamics:

Driver:

Rising global cancer prevalence

The continual rise in cancer incidence worldwide has markedly propelled the hadron therapy market. This trend is due to increasing numbers of patients seeking advanced and precise radiation therapies, with hadron therapy, especially proton and carbon ion modalities, emerging as highly effective options for complex and localized tumors. Additionally, the ongoing focus on precision medicine, combined with treatment-resistant cancer types, keeps up demand for more targeted treatments. The rapidly expanding cancer population globally ensures that the need for innovative oncological interventions, such as hadron therapy, will intensify, reinforcing market growth.

Restraint:

Limited number of treatment centers globally

The high capital investment required for constructing and operating hadron therapy centers severely limits their global distribution. These facilities demand extensive infrastructure, including cyclotrons or synchrotrons and robust radiation shielding, while also relying on a highly trained workforce. Complex regulatory approval processes and a lack of standardized reimbursement policies create additional hurdles, curtailing market penetration, particularly in emerging markets. Consequently, this scarcity restricts patient access and slows down the broader acceptance of hadron therapy worldwide, restraining market expansion.

Opportunity:

Integration of AI in treatment planning and imaging

AI-driven systems streamline repetitive and time-consuming processes, such as auto-segmentation of organs-at-risk and adaptive re-planning, resulting in more efficient workflows and reducing human variability. These advances enable clinicians to rapidly generate sophisticated, patient-specific treatment plans, boosting both the precision and confidence of therapy delivery. As AI technologies continue to evolve and gain regulatory approval, they promise not only operational efficiencies but also enhanced clinical outcomes for patients undergoing hadron therapy.

Threat:

High installation and operational costs

High installation and operational costs continue to act as formidable barriers, as establishing these facilities involves investments topping tens of millions of dollars due to the need for specialized equipment and rigorous building requirements. Ongoing expenses, such as expert staff salaries and maintenance of advanced technology, add further financial strain. These costs can make treatments prohibitively expensive for patients and challenge health insurers. These financial obstacles are expected to persist as a significant threat to sustained growth.

Covid-19 Impact:

The Covid-19 pandemic created a temporary setback for the hadron therapy market by disrupting healthcare delivery and shifting resources to pandemic response. Delays in the installation and commissioning of new centers occurred due to supply chain interruptions and travel restrictions, while routine treatments were postponed or slowed to accommodate infection control protocols. Patient access dwindled, particularly due to international travel limitations and resource allocation to critical care. However, despite these short-term disruptions, the hadron therapy sector has shown resilience, with a gradual return to regular operations as healthcare systems adapt and patient demand rebounds.

The proton therapy segment is expected to be the largest during the forecast period

The proton therapy segment is expected to account for the largest market share during the forecast period, attributed to its validated safety profile and ability to deliver highly targeted doses with minimal damage to surrounding tissues. Growing clinical evidence supports its superiority in reducing side effects, making it especially suitable for vulnerable populations such as pediatric patients and those with tumors near critical organs. Furthermore, expanded installation of proton therapy systems in leading hospitals and rising government support for non-invasive cancer care will solidify this segment's leadership position.

The pediatric cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatric cancer segment is predicted to witness the highest growth rate, driven primarily by the heightened need for less toxic, more effective treatments for children, who are especially susceptible to long-term side effects from conventional radiation therapies. Increasing incidence rates of pediatric cancers worldwide, coupled with the push for clinical trial advancements and technological innovation in pediatric care protocols, are fueling this trend. Additionally, government grants and global health initiatives are further catalyzing the adoption of hadron therapy for pediatric oncology applications, generating robust growth prospects.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by its advanced healthcare infrastructure, strong research capabilities, and substantial public and private investments in cancer treatment technologies. The region benefits from early adoption of innovative therapies and established clinical networks, which facilitate widespread patient access. Additionally, the presence of leading equipment manufacturers and ongoing initiatives to expand hadron therapy facilities, particularly in the United States, ensure that North America remains at the forefront of clinical adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Investments in upgrading healthcare infrastructure, rising cancer prevalence, and heightened government and private sector funding underpin this surge. Japan and China are making significant inroads with state-of-the-art research hubs and newly established hadron centers, while India is emerging as a promising market owing to increased awareness and public-private partnerships. These efforts are fostering rapid adoption, making Asia Pacific the epicenter for future growth.

Key players in the market

Some of the key players in Hadron Therapy Market include Ion Beam Applications SA (IBA), Varian Medical Systems, Inc., Hitachi, Ltd., Mevion Medical Systems, Inc., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, Koninklijke Philips N.V., Advanced Oncotherapy PLC, Optivus Proton Therapy, Inc., Elekta AB, ProTom International, Inc., ProNova Solutions, LLC, Toshiba Energy Systems & Solutions Corporation, Provision Healthcare, LLC, Shinva Medical Instrument Co., Ltd., Danfysik A/S, and Siemens Healthineers AG.

Key Developments:

In June 2025, IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has been unveiled at the 2025 PTCOG (Particle Therapy Co-Operative Group) annual conference taking place in Buenos Aires, Argentina.

In January 2025, Mevion Medical Systems, the leader in compact proton therapy solutions, proudly announces the delivery of its first MEVION S250-FIT Proton Therapy System(TM)* to Stanford Health Care. This marks a significant milestone in the development of proton therapy, as it is the first time a full proton therapy system is to be installed in a room like a conventional linear accelerator (LINAC) vault. The new system represents a new frontier in proton therapy, integrating cutting-edge technology to enhance patient outcomes.

In December 2024, Mevion Medical Systems, a leading provider of compact proton therapy solutions, today announced that it has received approval from the National Medical Products Administration (NMPA) of China for its MEVION S250i Proton Therapy System. This marks the first time this advanced technology has been approved in China, making Mevion the first company to offer a compact, integrated proton solution to Chinese cancer patients.

Type of Particles Covered:

Proton Therapy
Carbon Ion Therapy
Other Ion Therapy

Components:

Equipment
Software
Services

Cancer Types Covered:

Pediatric Cancer
Prostate Cancer
Head & Neck Cancer
Lung Cancer
Liver Cancer
Breast Cancer
Eye Cancer
Bone & Soft Tissue Cancer
Central Nervous System (CNS) Cancer
Other Cancer Types

End Users Covered:

Hospitals
Dedicated Proton/Hadron Therapy Centers
Research & Academic Institutions
Private Oncology Clinics

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Hadron Therapy Market, By Type of Particle

5.1 Introduction
5.2 Proton Therapy
- 5.2.1 Single-Room Systems
- 5.2.2 Multi-Room Systems
5.3 Carbon Ion Therapy
5.4 Other Ion Therapy

6 Global Hadron Therapy Market, By Component

6.1 Introduction
6.2 Equipment
- 6.2.1 Particle Accelerators
- 6.2.2 Beam Delivery Systems
- 6.2.3 Patient Positioning & Immobilization Systems
- 6.2.4 Imaging Systems
6.3 Software
- 6.3.1 Treatment Planning Software
- 6.3.2 Patient Management Software
- 6.3.3 Quality Assurance (QA) Software
6.4 Services
- 6.4.1 Installation and Maintenance Services
- 6.4.2 Training and Education
- 6.4.3 Consulting Services

7 Global Hadron Therapy Market, By Cancer Type

7.1 Introduction
7.2 Pediatric Cancer
7.3 Prostate Cancer
7.4 Head & Neck Cancer
7.5 Lung Cancer
7.6 Liver Cancer
7.7 Breast Cancer
7.8 Eye Cancer
7.9 Bone & Soft Tissue Cancer
7.10 Central Nervous System (CNS) Cancer
7.11 Other Cancer Types

8 Global Hadron Therapy Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Dedicated Proton/Hadron Therapy Centers
8.4 Research & Academic Institutions
8.5 Private Oncology Clinics

9 Global Hadron Therapy Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Ion Beam Applications SA (IBA)
11.2 Varian Medical Systems, Inc.
11.3 Hitachi, Ltd.
11.4 Mevion Medical Systems, Inc.
11.5 Sumitomo Heavy Industries, Ltd.
11.6 Mitsubishi Electric Corporation
11.7 Koninklijke Philips N.V.
11.8 Advanced Oncotherapy PLC
11.9 Optivus Proton Therapy, Inc.
11.10 Elekta AB
11.11 ProTom International, Inc.
11.12 ProNova Solutions, LLC
11.13 Toshiba Energy Systems & Solutions Corporation
11.14 Provision Healthcare, LLC
11.15 Shinva Medical Instrument Co., Ltd.
11.16 Danfysik A/S
11.17 Siemens Healthineers AG

簡介目錄圖表

List of Tables

Table 1 Global Hadron Therapy Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Hadron Therapy Market Outlook, By Type of Particle (2024-2032) ($MN)
Table 3 Global Hadron Therapy Market Outlook, By Proton Therapy (2024-2032) ($MN)
Table 4 Global Hadron Therapy Market Outlook, By Single-Room Systems (2024-2032) ($MN)
Table 5 Global Hadron Therapy Market Outlook, By Multi-Room Systems (2024-2032) ($MN)
Table 6 Global Hadron Therapy Market Outlook, By Carbon Ion Therapy (2024-2032) ($MN)
Table 7 Global Hadron Therapy Market Outlook, By Other Ion Therapy (2024-2032) ($MN)
Table 8 Global Hadron Therapy Market Outlook, By Component (2024-2032) ($MN)
Table 9 Global Hadron Therapy Market Outlook, By Equipment (2024-2032) ($MN)
Table 10 Global Hadron Therapy Market Outlook, By Particle Accelerators (2024-2032) ($MN)
Table 11 Global Hadron Therapy Market Outlook, By Beam Delivery Systems (2024-2032) ($MN)
Table 12 Global Hadron Therapy Market Outlook, By Patient Positioning & Immobilization Systems (2024-2032) ($MN)
Table 13 Global Hadron Therapy Market Outlook, By Imaging Systems (2024-2032) ($MN)
Table 14 Global Hadron Therapy Market Outlook, By Software (2024-2032) ($MN)
Table 15 Global Hadron Therapy Market Outlook, By Treatment Planning Software (2024-2032) ($MN)
Table 16 Global Hadron Therapy Market Outlook, By Patient Management Software (2024-2032) ($MN)
Table 17 Global Hadron Therapy Market Outlook, By Quality Assurance (QA) Software (2024-2032) ($MN)
Table 18 Global Hadron Therapy Market Outlook, By Services (2024-2032) ($MN)
Table 19 Global Hadron Therapy Market Outlook, By Installation and Maintenance Services (2024-2032) ($MN)
Table 20 Global Hadron Therapy Market Outlook, By Training and Education (2024-2032) ($MN)
Table 21 Global Hadron Therapy Market Outlook, By Consulting Services (2024-2032) ($MN)
Table 22 Global Hadron Therapy Market Outlook, By Cancer Type (2024-2032) ($MN)
Table 23 Global Hadron Therapy Market Outlook, By Pediatric Cancer (2024-2032) ($MN)
Table 24 Global Hadron Therapy Market Outlook, By Prostate Cancer (2024-2032) ($MN)
Table 25 Global Hadron Therapy Market Outlook, By Head & Neck Cancer (2024-2032) ($MN)
Table 26 Global Hadron Therapy Market Outlook, By Lung Cancer (2024-2032) ($MN)
Table 27 Global Hadron Therapy Market Outlook, By Liver Cancer (2024-2032) ($MN)
Table 28 Global Hadron Therapy Market Outlook, By Breast Cancer (2024-2032) ($MN)
Table 29 Global Hadron Therapy Market Outlook, By Eye Cancer (2024-2032) ($MN)
Table 30 Global Hadron Therapy Market Outlook, By Bone & Soft Tissue Cancer (2024-2032) ($MN)
Table 31 Global Hadron Therapy Market Outlook, By Central Nervous System (CNS) Cancer (2024-2032) ($MN)
Table 32 Global Hadron Therapy Market Outlook, By Other Cancer Types (2024-2032) ($MN)
Table 33 Global Hadron Therapy Market Outlook, By End User (2024-2032) ($MN)
Table 34 Global Hadron Therapy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 35 Global Hadron Therapy Market Outlook, By Dedicated Proton/Hadron Therapy Centers (2024-2032) ($MN)
Table 36 Global Hadron Therapy Market Outlook, By Research & Academic Institutions (2024-2032) ($MN)
Table 37 Global Hadron Therapy Market Outlook, By Private Oncology Clinics (2024-2032) ($MN)